Zinc (Zn 2 + ) is the most abundant trace element in cells and is essential for a vast number of catalytic, structural, and regulatory processes. Mounting evidence indicates that like calcium (Ca 2 + ), intracellular Zn 2 + pools are redistributed for specifi c cellular functions. This occurs through the regulation of 24 Zn 2 + transporters whose localization and expression is tissue and cell specifi c. We propose that the complement and regulation of Zn 2 + transporters expressed within a given cell type refl ects the function of the cell itself and comprises a ' Zn 2 + network. ' Importantly, increasing information implicates perturbations in the Zn 2 + network with metabolic consequences and disease. Herein, we discuss our current understanding of Zn 2 + transporters from the perspective of a Zn 2 + network in four specifi c tissues with unique Zn 2 + requirements (mammary gland, prostate, pancreas, and brain). Delineating the entire Zn 2 + transporting network within the context of unique cellular Zn 2 + needs is important in identifying critical gaps in our knowledge and improving our understanding of the consequences of Zn 2 + dysregulation in human health and disease.
Introduction
Zinc (Zn 2 + ) is the second most abundant trace element in living organisms (Vallee and Falchuk , 1993 ) and is the most abundant trace element in cells. Zn 2 + is clearly not a trace element from the perspective of the cell (Eide , 2006 ) , as Zn 2 + is required for an immense number of catalytic, structural, and regulatory functions in specifi c subcellular compartments, including gene transcription in the nucleus (Vallee and Falchuk , 1993 ) , ATP production and apoptosis in the mitochondria , enzyme activation in the secretory pathway (Fukunaka et al. , 2009 ) , and microtubule formation (Oteiza et al. , 1990 ) and cell signaling in the cytoplasm (Yamasaki et al. , 2007 ) . Given the vast number of cellular processes that concurrently require Zn 2 + , cells respond to changes in cellular Zn 2 + demands and/or external cues by redistributing intracellular Zn 2 + pools. Since the discovery of the fi rst Zn 2 + transporter in 1995 (Palmiter and Findley , 1995 ) , 24 Zn 2 + transporters have been identifi ed, which function to maintain intracellular Zn 2 + homeostasis by tight regulation of Zn 2 + acquisition, compartmentalization, sequestration, and effl ux mechanisms. We propose that the complement of Zn 2 + transporters expressed within a given cell refl ects the specifi c function of the cell type itself and comprises what we refer to as the ' Zn 2 + network. '
Conceptualizing Zn 2 + networks
The 24 Zn 2 + -transporting proteins described in mammals can be divided into two distinct families, the Z rt-, i rt-like p rotein (Zip, SLC39A ) family of Zn 2 + importers and the Zn 2 + T ransporter (ZnT, SLC30A ) family of Zn 2 + exporters. Whereas Zips import Zn 2 + into the cell or transport Zn 2 + from within a subcellular compartment into the cytoplasm, ZnTs export Zn 2 + out of the cell or transport Zn 2 + from the cytoplasm into subcellular compartments. Structurally, Zips have eight transmembrane domains with N-and C-termini on the noncytoplasmic face. In contrast, the majority of ZnTs consist of six transmembrane domains (ZnT5 is the exception with nine additional transmembrane domains) with N-and C-termini within the cytoplasm. Transmembrane domains 3 -4 and 4 -5 on Zips and ZnTs, respectively, contain a long loop with a histidine-rich domain that is thought to facilitate metal binding. Most Zn 2 + transporters are at least partially characterized and are the subject of a number of reviews (Kambe et al. , 2004 ; Cousins et al. , 2006 ; ). Based on this information, various generalizations, such as the majority of ZnTs, are found in intracellular compartments (Cousins et al. , 2006 ) and are localized to acidic vesicular compartments (Fukada and Kambe , 2011 ) and that most Zips are localized to the cell membrane (Cousins et al. , 2006 ) have been made. Relevant to the concept of a cell-specifi c Zn 2 + network is the fact that Zn 2 + transporter expression and subcellular localization (e.g., nucleus, endoplasmic reticulum, the Golgi apparatus, mitochondria, vesicles, the cell membrane, etc.) is tissue and cell specifi c. This makes sense as the demand for Zn 2 + in a particular cell type is driven by the unique function(s) of that cell. One simple example is the redistribution of Zn 2 + to the nucleus that occurs in immature monocytes to induce macrophage transformation in response to a differentiation stimulus (Glesne et al. , 2006 ) . Interestingly, calcium (Ca 2 + ) pools are also redistributed during macrophage differentiation (Tasaka et al. , 1991 ) , suggesting that metal redistribution may be a key modulator of macrophage function and phenotype. In fact, emerging evidence suggests that similar to Ca 2 + , Zn 2 + acts as an intracellular signaling ion, and like Zn 2 + , Ca 2 + coordinates the regulation of many different cellular processes that are governed through a ' Ca 2 + network. ' The Ca 2 + network provides a framework for conceptualizing Zn 2 + networks. Intracellular Ca 2 + homeostasis is tightly controlled through Ca 2 + compartmentalization in intracellular compartments, termed Ca 2 + ' microdomains ' or ' hot spots ' such as the endo-/sarcoplasmic reticulum, mitochondria, Golgi apparatus, secretory granules, lysosomes, and endocytic vesicles (Rizzuto and Pozzan , 2006 ) . Fluctuations in Ca 2 + uptake/effl ux across the cell membrane or the redistribution of intracellular Ca 2 + pools (Bootman and Berridge , 1995 ) exert effects on bioenergetics, cell death, gene expression, protein metabolism, and secretion (Corbett and Michalak , 2000 ; Bravo et al. , 2012 ) . Dysregulation in the Ca 2 + network is implicated in neurodegenerative diseases such as Parkinson ' s and Alzheimer ' s, heart conditions ranging from cardiac arrhythmias to heart failure, diabetes and pancreatitis, skin disorders, and cancer (Lindholm et al. , 2006 ; Rizzuto and Pozzan , 2006 ; Brini and Carafoli , 2009 ). For instance, endoplasmic reticulum stress induces the redistribution of Ca 2 + from the endoplasmic reticulum to the mitochondria to stimulate mitochondrial bioenergetics (Bravo et al. , 2012 ) . Dysregulation in this process leads to prolonged endoplasmic reticulum stress and the concomitant transfer of Ca 2 + to mitochondria, which induces mitochondrial dysfunction and cell death (Bravo et al. , 2012 ) and is implicated in neurodegenerative diseases (Lindholm et al. , 2006 ) .
Recently, we found that the entire Zn 2 + network shifts during lactation to reallocate intracellular Zn 2 + pools to support the dramatic alterations that occur in mammary cell function (Kelleher et al. , 2012 ) . Dysregulation in mammary gland Zn 2 + metabolism results from alterations in the Zn 2 + network and is associated with breast cancer (Santoliquido et al. , 1976 ; Kagara et al. , 2007 ; Taylor et al. , 2007 ; Kelleher et al. , 2009 ). This provides the rationale for considering the role of Zn 2 + transporters within a ' functional network ' that shifts depending on cellular function, as opposed to exploring their functions as isolated entities as is the current paradigm. In this framework, Zn 2 + transporters that are of particular importance can be delineated and perturbations in the Zn 2 + network and the relationship to disease can be considered. The details of the relationship between Zn 2 + networks and cell-specifi c Zn 2 + demands are far from understood. Herein, we functionally organize our current understanding of Zn 2 + transport and metabolism into cell-specifi c Zn 2 + networks. In doing so, we aim to (1) improve our understanding of the regulation and dysregulation of Zn 2 + metabolism and (2) identify gaps in our current knowledge. We have chosen cell types within four specifi c tissues that have a unique requirement for Zn 2 + as examples of how the Zn 2 + network must redistribute Zn 2 + for specifi c cellular functions.
Mammary gland
The mammary gland phenotypically switches between expansion and regression during reproduction. During the transition from a quiescent to a secreting organ, dramatic shifts in numerous Zn 2 + -dependent processes (e.g., bioenergetics, cell cycle, apoptosis/autophagy, cytokine-and hormonedependent signaling, etc.) must occur in order to maintain the secretory epithelium. At the same time, the mammary gland must accumulate and secrete (McCormick et al. , 2010 ) an extraordinary amount of Zn 2 + ( ∼ 1 -3 mg/day) in response to lactogenic stimulation. Extensive redistribution of intracellular Zn 2 + pools must occur to accommodate the dramatic shifts in cellular Zn 2 + needs. Defects in the ability to accommodate these shifts impair the ability of the mammary gland to expand during pregnancy and produce milk during lactation.
In response to lactogenic stimulation, Zn 2 + is taken up by the cell, redistributed within subcellular compartments, and accumulated in secretory vesicles for transfer into milk. Using a systems biology approach, we characterized the dramatic shifts that occur in the Zn 2 + network in mammary epithelial cells during lactation (Figure 1 ) (Kelleher et al. , 2012 ) . These shifts provide important clues to the role of specifi c Zn 2 + transporters in breast function. Certain Zn 2 + transporters that are constitutively expressed may provide Zn 2 + for more refractory, basic cellular functions. Zn 2 + transporters that are signifi cantly increased may be key to processes that are particularly important during lactation such as acquisition of Zn 2 + from maternal circulation, maintenance of the secretory epithelium, or Zn 2 + accumulation into vesicles for secretion into milk. In addition, upregulation of Zn 2 + transporters in the secretory system may be involved in the production of milk constituents such as lactose, as Zn 2 + modulates the activity of the lactose synthase complex (Permyakov et al. , 1993 ) . Moreover, shifts in the localization of Zn 2 + transporters (Seo et al. , 2011 ) or Zn 2 + transporters that are decreased or not expressed at all (Kelleher et al. , 2012 ) Identifi cation of these specialized roles can predict regulatory mechanisms that may be critical in governing important Zn 2 + -dependent processes. For example, Zip3 and ZnT2 are regulated by the lactogenic hormone prolactin, which is consistent with their key roles in lactation (Kelleher and Lonnerdal , 2005 ; Qian et al. , 2009 ). Zip6 is regulated by estrogen (Manning et al. , 1988 ) , and thus it is reasonable that Zip6 expression is negligible during conditions of estrogen deprivation such as lactation. Several studies have shown that proinfl ammatory cytokines, such as IL-1 β and TNF α , Interestingly, proinfl ammatory cytokines are important for mammary gland development (Ustundag et al. , 2005 ) , suggesting the cytokine milieu in the mammary gland microenvironment may regulate the Zn 2 + network. Understanding the role and regulation of Zn 2 + metabolism in normal breast tissue is key to understanding the relevance of Zn 2 + dysregulation in breast disease. Malignant breast tissue hyperaccumulates Zn 2 + (Santoliquido et al. , 1976 ) and is correlated with cancer progression (Cui et al. , 2007 ) . However, breast cancer is a heterogeneous disease and it is likely that differences in Zn 2 + network dysregulation underlie functional differences between breast cancer subtypes [i.e., luminal, basal, and human epidermal receptor 2 (HER2) + tumors] (Hsiao et al. , 2010 ; Bertos and Park , 2011 ) (Table 1 ). Numerous studies document over-or underexpression of specifi c Zn 2 + transporters in breast tumors or breast cancer cell lines (Lee et al. , 2003 ; Kagara et al. , 2007 ; Taylor , 2008 ; Lopez et al. , 2011 ) . Several transporters are overexpressed (Zip6, Zip7, Zip10, and ZnT2) (Kagara et al. , 2007 ; Taylor , 2008 ; Lopez et al. , 2011 ) , and the expression of ZnT1 is reduced (Lee et al. , 2003 ) ; yet due to the marked heterogeneity of breast cancer subtypes, the functional consequences of these observations are only partially understood. Zip6 is thought to be a prognostic indicator of estrogen receptorpositive (ER + ) breast cancer (Kasper et al. , 2005 ) . Interestingly, Zip6 protein levels are negatively associated with tumor grade, level, and size (Kasper et al. , 2005 ) . Consistent with this observation, Zip6 attenuation in ER + breast cancer cell 
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Figure 1 The mammary gland zinc network in response to lactation. Red arrows indicate increases ( > 1.5-fold), black arrows indicate no change, and purple arrows indicate decreases in zinc transporter expression in response to lactation. ER, endoplasmic reticulum. Adapted from Kelleher et al. (2012) . (Shen et al. , 2009 ; Lopez and Kelleher , 2010 ) , increases mitochondrial membrane potential, and decreases apoptosis (Lopez and Kelleher , 2010 ) . This functionally implicates Zip6 in mobilizing Zn 2 + from the endoplasmic reticulum (Taylor and Nicholson , 2003 ; Kasper et al. , 2005 ) and modulating mechanisms that restrict epithelial-to-mesenchymal transition (EMT). Zip7 is localized to the endoplasmic reticulum where it functions to increase the mobilization of Zn 2 + into the cytoplasm (Hogstrand et al. , 2009 ). Phosphorylation of Zip7 signals Zn 2 + release from the endoplasmic reticulum, which is thought to inactivate protein phosphatases, shifting MAPKs and tyrosine kinases such as EGFR, HER2, IGF1R, and Src to their active phosphorylated states (Hogstrand et al. , 2009 ; Taylor et al., 2012 ) . This suggests that endoplasmic reticulum Zn 2 + pools are a key modulator of intracellular signaling, which may be specifi cally dysregulated in breast cancer. In contrast, elevated Zip10 expression is associated with lymph node metastasis in human breast tumor samples and estrogen receptor-negative (ER-) cell lines (Kagara et al. , 2007 ) . Invasive cells express greater Zip10 and have lower levels of E-cadherin and higher levels of vimentin. This functionally implicates Zip10 and perhaps dysregulated Zn 2 + uptake in invasion and metastasis in breast cancer. In addition, ER + cells have greater expression of ZnT2, which is associated with increased vesicularized Zn 2 + pools . ZnT2 attenuation redistributes Zn 2 + into the cytoplasm and results in cell death , implicating vesicular Zn 2 + sequestration as a protective mechanism that may be dysregulated in breast cancer.
Cytokines and hormones may contribute to not only functionally/physiologically relevant shifts in intracellular Zn 2 + pools but also to the dysregulation of Zn 2 + networks that contribute to disease. The antiestrogen tamoxifen sequesters Zn 2 + in lysosomes, which induces autophagic cell death (Hwang et al. , 2010 ) . Overtime, ER + tumors become resistant to antiestrogens, leading to an increased Zn 2 + accumulation and a more aggressive phenotype (Taylor et al. , 2007 ) . This is particularly interesting as Zip7 and Zip8 (and the kinases listed above) are upregulated in antiestrogen-resistant cell lines (Taylor et al. , 2007 ) . It is important to emphasize that the Zn 2 + transporters dysregulated in breast cancer have been explored as isolated entities and not within the context of a Zn 2 + network. While dysregulation of isolated Zn 2 + transporters provides important insight into their role in unique cellular functions, we will not fully understand the implications and consequences of Zn 2 + dysregulation in breast disease until we understand the functional consequences of Zn 2 + network dysregulation in different breast cancer subtypes.
Prostate
The prostate contains more Zn 2 + than any other soft tissue. High Zn 2 + inhibits mitochondrial aconitase, thereby preventing citrate oxidation so citrate can be secreted into prostate fl uid . High levels of Zn 2 + accumulate in the mitochondria (Liu et al. , 1997 ) , although a Zn 2 + transporter responsible for mitochondrial Zn 2 + import has not been identifi ed (Guan et al. , 2003 ) . In addition to modulating citrate levels, an enormous amount of Zn 2 + [ ∼ 500 μ g/ml (Costello and Franklin , 1998 ) ] is secreted into the prostate fl uid for sperm release, motility, and fertility (Sorensen et al. , 1999 ) .
Similar to the mammary gland, Zn 2 + must be taken up by the prostate cell, redistributed within subcellular compartments, and accumulated in secretory vesicles (Costello and Franklin , 1998 ) . While the expression of numerous Zn 2 + transporters has been documented in the prostate (Table 2 ) , their contribution to prostate function is not well understood (Figure 2 ). Zip1 is localized primarily to the basolateral membrane of epithelial cells in the peripheral zone of the human prostate circulation. In contrast, Zip2 and Zip3 are localized to the apical membrane of human prostate cells (Desouki et al. , 2007 ) , suggesting that Zip2 and Zip3 function to import Zn 2 + from prostate fl uid to maintain intracellular Zn 2 + homeostasis in an autocrine or paracrine manner. Zn 2 + accumulation into vesicles for secretion is critical for prostate cell function. ZnT2 expression is positively correlated with the high Zn 2 + concentration measured in the prostate ' s dorsolateral lobe (Iguchi et al. , 2002 ). Iguchi and colleagues found that ZnT2 resides in a lysosomal-like compartment (Iguchi et al. , 2002 ) , perhaps providing Zn 2 + for secretion. ZnT4-7 accumulate Zn 2 + in the secretory compartment (Kirschke and Huang , 2008 ) and may therefore provide Zn 2 + to Zn 2 + -dependent enzymes in the secretory system (Fukunaka et al. , 2009 ), such as acid phosphatase for release into the prostate fl uid. Furthermore, the expression and localization of various Zn 2 + transporters changes throughout sexual maturation, suggesting that the Zn 2 + network is developmentally regulated (Kirschke and Huang , 2008 ) . This parallels the Zn 2 + accumulation in the secretory compartment (Kirschke and Huang , 2008 ) and coincides with the hormonal control of prostate growth (Donjacour and Cunha , 1988 ) . Moreover this suggests that hormones such as androgens may be key regulators of the prostate Zn 2 + network. Further studies are required to understand the regulation of the Zn 2 + network in prostate. Prostate lobes vary in the amount of Zn 2 + they contain. The dorsolateral lobe in rodent and the peripheral lobe in human prostate contain the greatest amount of Zn 2 + . Perhaps not coincidently, the majority of prostate cancers originate in these lobes (Kirschke and Huang , 2008 ) . As the prostate becomes malignant, prostate Zn 2 + concentration drops ∼ 75 -90 % . The limited information available can be used to speculate the dysregulation in the Zn 2 + network that accounts for the depletion in Zn 2 + . Redistribution of Zn 2 + pools in the Golgi apparatus through decreased ZnT7 (Lue et al. , 2011 ) and increased expression of ZnT4 (Henshall et al. , 2003 ) may promote EMT via ERK-mediated signaling (Tepaamorndech et al. , 2011 ) . Zip6 over-expression, which drives EMT in human prostate cancer cells (ARCaP) and mice (Lue et al. , 2011 ) may function to increase cytoplasmic Zn 2 + pools. This may function to shift the Zn 2 + network to increase Zn 2 + effl ux through ZnT1 (Iguchi et al. , 2004 ) , thereby depleting intracellular Zn 2 + pools. Ultimately, expression of Zip1 -4 is decreased Desouki et al. , 2007 ; Chen et al. , 2011 ) perhaps further exacerbating the hallmark of Zn 2 + depletion in prostate cancers. Clearly, our understanding is limited, which argues that the Zn 2 + network in the prostate must be considered in order to fully grasp the mechanisms responsible for prostate cancer.
Pancreas
Both the exocrine and endocrine pancreas have unique requirements for Zn 2 + . Although the expression of numerous Zn 2 + transporters has been documented in the endocrine pancreas, information on Zn 2 + transporters in the exocrine pancreas is limited (Table 3 ). The exocrine pancreas places a large burden on systemic and intracellular Zn 2 + pools. Following a meal, there is a net increase in Zn 2 + in the duodenum ( ∼ 3 mg Zn 2 + more than the meal itself) (Matseshe et al. , 1980 ) . This refl ects the large amount of Zn 2 + -dependent pancreatic enzymes that are secreted from acinar cells to aid in the digestion of food. Despite the high intracellular Zn of the pancreas are involved. ZnT2 is localized to zymogen granules, providing Zn 2 + to these proenzyme-containing vesicles (Guo et al. , 2010 ) and facilitating Zn 2 + secretion . Indeed, ZnT2 is increased in response to glucocorticoids in pancreatic acinar cells and, similar to the mammary gland, signals through the JAK2/STAT5 pathway (Qian et al. , 2009 ; Guo et al. , 2010 ) . Further research is warranted to fully develop the Zn 2 + network in the exocrine pancreas and understand its regulation.
The endocrine pancreas controls blood glucose homeostasis through the regulated secretion of insulin and glucagon by pancreatic β -and α -cells, respectively. β -cells make up 60 -80 % of the islet population and contain among the highest Zn 2 + content in the body (Clifford and MacDonald , 2000 ) . Zn 2 + plays a structural role in the synthesis, storage, and secretion of insulin in a hormonally regulated manner (Emdin et al. , 1980 ) . Trimers of insulin dimers are bound by two structural Zn 2 + ions forming a functional insulin hexamer (Hill et al. , 1991 ) . In response to an external stimulus (e.g., elevated blood glucose concentrations), insulin and Zn 2 + are exocytosed from the cell where Zn 2 + is thought to act in a paracrine fashion to suppress the release of glucagon from α -cells (Chimienti et al. , 2005 ) . Following each stimulatory event, Zn 2 + must be taken up by the β -cell to replenish secreted Zn 2 + , redistributed within subcellular compartments, and accumulated in insulin-containing secretory vesicles. While it is unclear how Zn 2 + is imported into the β -cell, ZnT8 (which shares homology with ZnT2) is localized to the insulin-containing secretory vesicles where it functions to compartmentalize Zn 2 + in insulin-containing secretory granules (Chimienti et al. , 2005 ) . Zip4 is abundantly expressed and its co-localization with insulin in murine islets (Dufner -Beattie et al., 2004 ) curiously suggests it may export Zn 2 + out of the secretory granules. The role of other members of the Zn 2 + network is limited and often confl icting depending on the cell line, species, and strain ( Figure 3B ). MIN6 cells express Zip1-14 and ZnT1-9 (El Muayed et al. , 2010 ) ; however, their roles are not understood. ZnT5 and ZnT7 are abundant in pancreatic β -cells and are localized to secretory granules and the Golgi apparatus (Kambe et al. , 2002 ; Huang et al. , 2010 ) and thus may contribute to the activation of various Zn 2 + -dependent enzymes in the secretory system (Suzuki et al. , 2005 ) , such as the insulin-processing Zn 2 + -dependent enzyme carboxypeptidase-E. Prolonged exposure to elevated glucose increases free cytosolic Zn 2 + in mouse pancreatic islets (Bellomo et al. , 2011 ) , perhaps driven by increases in Zip6, Zip7, and Zip8 (Bellomo et al. , 2011 ) . This reveals that the Zn 2 + network in pancreatic β -cells shifts to provide Zn 2 + for insulin processing during periods of increased requirement (e.g., following a meal). Importantly, it implies that the Zn 2 + network may be dysregulated in conditions of uncontrolled blood glucose homeostasis, such as diabetes and metabolic syndrome.
Much interest has been devoted to the relationship between diabetes and disturbances in Zn 2 + transport in pancreatic β -cells. The focus has largely been placed on ZnT8, as both type 1 and type 2 diabetes are associated with defects in ZnT8 [reviewed by Rutter (2010) ]. It is likely that the entire Zn 2 + network shifts to provide Zn 2 + for accumulation in insulincontaining granules, and when these processes are compromised, insulin packaging and secretion are insuffi cient. For instance, proinfl ammatory cytokines associated with type 2 diabetes alter Zn 2 + transporter expression in MIN6 cells (El Muayed et al. , 2010 ) . IL-1 β and TNF α increase expression of Zip1, Zip4, and Zip11, while expression of Zip8, Zip10, Zip13, Zip14, ZnT5, and ZnT8 decreases. Increased expression of Zip4 in response to proinfl ammatory cytokines suggests that Zn 2 + is redistributed from secretory granules. Consistent with this hypothesis, shifts in the Zn 2 + network are associated with decreases in labile Zn 2 + pools (El Muayed et al. , 2010 ) . A better understanding of the Zn 2 + network in β -cells will allow us to understand how infl ammatory cues contribute to dysregulated metabolic processes, such as diabetes.
There is evidence that Zn 2 + transport is dysregulated in pancreatic cancers as well. Zip4 is overexpressed in human pancreatic tumors and cell lines (Li et al. , 2007 ) . Forced overexpression of Zip4 augments the pathogenesis and progression (Li et al. , 2007 ) through increased activity of factors that promote angiogenesis, invasion, and metastasis, such as MMPs (Zhang et al. , 2010a ) and increased IL-6/ STAT3 signaling (Zhang et al. , 2010b ) . Recently, Costello and colleagues found a signifi cant reduction in pancreatic Zn 2 + concurrent with the absence of Zip3 in pancreatic adenocarcinomas (Costello et al. , 2011 ) . It is therefore conceivable that Zip4 overexpression may result from the depletion in cellular Zn 2 + pools (Andrews , 2008 ) , underscoring the importance of characterizing the entire complement of Zn 2 + transporters within a specifi c tissue when considering instances of their dysregulation, such as cancer.
Brain
Approximately 20 % of total brain Zn 2 + is concentrated in synaptic vesicles of a subset of glutamatergic neurons (Cole et al. , 1999 ) for release at the synapse during neuronal activity. Zn 2 + is exocytosed as an extracellular signaling ion and interacts with postsynaptic targets to modulate synaptic transmission and plasticity and signal transduction (Sindreu and Storm , 2011 ) . Zn 2 + availability has profound effects on neurological function (Colvin et al. , 2003 ) ; therefore, intracellular levels are tightly regulated. Following each stimulatory event, Zn 2 + must be taken up by the neuron, redistributed within subcellular compartments, and accumulated in synaptic vesicles. Owing to the requisite Zn 2 + required for normal brain function, Zn 2 + fl ux across the blood-brain barrier responds to Zn 2 + status (McClung and Bobilya , 1999 ; Lehmann et al. , 2002 ) . Although Zn 2 + fl ux in neurons occurs through a number of different channels and receptors, such as voltage-gated Ca 2 + channels and Ca 2 + -and Zn 2 + -permeable GluR2-lacking AMPA receptors (Sensi et al. , 2009 ), the expression of few Zn 2 + transporters has been documented (Table 4 ) . Zip1, Zip3 , and Zip6 (Chowanadisai et al. , 2008 ) and ZnT1 (Sekler et al. , 2002 ) are thought to contribute to Zn 2 + infl ux and effl ux in the cell body of the presynaptic glutamatergic neurons, respectively. ZnT3, which shares homology with ZnT2 and ZnT8, accumulates Zn 2 + in synaptic vesicles. The importance of ZnT3 in Zn 2 + accumulation in synaptic vesicles is underscored by a marked reduction in synaptic Zn 2 + in ZnT3 knockout mice (Cole et al. , 1999 ) .
Far less is known regarding the Zn 2 + redistribution in neurons that is required to provide Zn 2 + for accumulation into synaptic vesicles in the axon terminal ( Figure 4 ) ; however, the Zn 2 + network likely includes mitochondria, vesicles, and lysosomes (Colvin et al. , 2003 ; Sensi et al. , 2009 . This suggests that during times of increased or decreased Zn 2 + availability, MT-III modulates the availability of free Zn 2 + for incorporation into synaptic vesicles for neuronal activity. Zn 2 + is released from MT-III by oxidative stress and ischemic acidosis, which increases cell death (Shuttleworth and Weiss , 2011 ) . The relationship between ischemia and Zn 2 + is well established and is reviewed elsewhere (Weiss et al. , 2000 ; Sensi et al. , 2009 ; Shuttleworth and Weiss , 2011 ) . Dysregulated Zn 2 + movement across the synapse (from the pre-to postsynaptic neuron) redistributes Zn 2 + to the mitochondria and lysosomes (Frederickson et al. , 1989 ; Weiss et al. , 2000 ) leading to cell death though apoptotic and autophagic mechanisms, respectively (Sensi et al. , 2009 ).
Interestingly, Ca
2 + was fi rst thought to be responsible for ischemic cell death in neurons until it was recognized that these Ca 2 + -sensitive probes and Ca 2 + chelators were not specifi c for Ca 2 + and have a higher affi nity for Zn 2 + (Sensi et al. , 2009 ). Few studies have examined Zn 2 + transporters that contribute to the dysregulated movement of Zn 2 + in brain ischemia. Ischemia increases ZnT1 (Tsuda et al. , 1997 ) , most likely to export Zn 2 + out of the cell and prevent Zn 2 + -induced neurotoxicity. Noebels ' group showed that postsynaptic Zn 2 + uptake is reduced in Zip1/3 null mice, which attenuates neurodegeneration . In the same study, the authors also showed less neuronal cell damage in response to kainateinduced injury in ZnT3-null mice , suggesting that a reduction in synaptic Zn 2 + from ZnT3-containing vesicles and the subsequent reduction in postsynaptic Zn 
Concluding remarks and future directions
Undoubtedly, Zn 2 + is a critical modulator of a vast number of cellular and metabolic processes. It seems reasonable that Zn 2 + metabolism is tightly regulated through the coordinated interaction of Zn 2 + transporters that function within a complex network to compartmentalize Zn 2 + for specifi c functions. The ' network hypothesis ' requires that the role and regulation of the entire network of Zn 2 + transporters within a particular system be considered to better understand the role of Zn 2 + in modulating cell function and how Zn 2 + metabolism is regulated. This is particularly important with respect to understanding the relationship between Zn 2 + dysregulation and disease. Clearly, our current understanding of how Zn 2 + is distributed within a network in most cell types and what cellular processes are regulated as a result is limited. Although utilizing a systems biology approach to investigate Zn 2 + metabolism poses many challenges: it offers the potential to better understand Zn 2 + metabolism in complex systems and develop innovative strategies for therapeutic interventions.
